March 13, 2018 / 11:50 AM / 2 months ago

BRIEF-Actinium Announces FDA Clearance Of IND For Phase 1 Trial Of Actimab-A In Combination With CLAG-M For Patients With Relapsed Or Refractory AML

March 13 (Reuters) - Actinium Pharmaceuticals Inc:

* ACTINIUM ANNOUNCES FDA CLEARANCE OF IND FOR PHASE 1 TRIAL OF ACTIMAB-A IN COMBINATION WITH CLAG-M FOR PATIENTS WITH RELAPSED OR REFRACTORY AML

* ACTINIUM PHARMA- ‍COMBINATION TRIAL EXPANDS ADDRESSABLE PATIENT POPULATION FOR ACTINIUM’S CD33 PROGRAM INTO RELAPSED/REFRACTORY PATIENTS FIT FOR CHEMOTHERAPY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below